Holen Sie sich die Stockscreener-App
23.57
5.00%
-1.24
Schlusskurs vom Vortag:
$24.81
Offen:
$24.74
24-Stunden-Volumen:
345.91K
Relative Volume:
1.01
Marktkapitalisierung:
$758.68M
Einnahmen:
$4.12M
Nettoeinkommen (Verlust:
$-56.68M
KGV:
-4.2523
EPS:
-5.5429
Netto-Cashflow:
$-51.44M
1W Leistung:
-3.00%
1M Leistung:
+10.19%
6M Leistung:
+11.97%
1J Leistung:
-18.07%
1-Tages-Spanne:
$22.81
$25.22
1-Wochen-Bereich:
$22.81
$25.41
52-Wochen-Spanne:
$13.37
$32.27
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Firmenname
Dianthus Therapeutics Inc
Sektor
Branche
Telefon
929-999-4055
Adresse
7 TIMES SQUARE, NEW YORK
Vergleichen Sie DNTH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
23.57 | 798.59M | 4.12M | -56.68M | -51.44M | -5.5429 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-02 | Eingeleitet | William Blair | Outperform |
| 2024-12-20 | Eingeleitet | TD Cowen | Buy |
| 2024-10-03 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-26 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-06-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-02-15 | Eingeleitet | Stifel | Buy |
| 2023-12-26 | Eingeleitet | Jefferies | Buy |
| 2023-11-22 | Eingeleitet | Wedbush | Outperform |
| 2023-10-30 | Eingeleitet | Guggenheim | Buy |
| 2023-09-28 | Eingeleitet | Raymond James | Outperform |
| 2022-08-25 | Herabstufung | Goldman | Buy → Neutral |
| 2022-01-06 | Hochstufung | Goldman | Neutral → Buy |
| 2021-08-20 | Fortgesetzt | Goldman | Neutral |
| 2021-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-22 | Bestätigt | B. Riley Securities | Buy |
| 2021-06-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-18 | Eingeleitet | B. Riley Securities | Buy |
| 2021-01-07 | Eingeleitet | Mizuho | Buy |
| 2020-06-08 | Hochstufung | Goldman | Neutral → Buy |
| 2019-03-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-03-15 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Dianthus Therapeutics Inc Aktie (DNTH) Neueste Nachrichten
Heatmap analysis for Dianthus Therapeutics Inc. and competitorsCEO Change & AI Driven Price Predictions - Newser
Walleye Capital LLC Raises Stock Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Will Dianthus Therapeutics Inc. stock go up soon2025 Price Action Summary & Safe Entry Zone Tips - Newser
Is Dianthus Therapeutics Inc. trending in predictive chart modelsOil Prices & Community Supported Trade Ideas - Newser
Momentum divergence signals in Dianthus Therapeutics Inc. chartMarket Risk Report & Free Reliable Trade Execution Plans - Newser
Best data tools to analyze Dianthus Therapeutics Inc. stock2025 Short Interest & Fast Moving Trade Plans - Newser
Does Dianthus Therapeutics Inc. fit your quant trading modelJuly 2025 Highlights & Entry Point Confirmation Signals - Newser
Can swing trading help recover from Dianthus Therapeutics Inc. lossesSwing Trade & Daily Price Action Insights - Newser
Leading vs lagging indicators on Dianthus Therapeutics Inc. performanceEarnings Recap Summary & Precise Trade Entry Recommendations - Newser
Is Dianthus Therapeutics Inc. stock poised for growthJuly 2025 Earnings & Trade Opportunity Analysis - Newser
Can Dianthus Therapeutics Inc. rally from current levelsWeekly Investment Recap & Consistent Return Investment Signals - Newser
Real time scanner hits for Dianthus Therapeutics Inc. explained2025 Dividend Review & Breakout Confirmation Trade Signals - Newser
What data driven models say about Dianthus Therapeutics Inc.’s futurePortfolio Gains Summary & Free Expert Verified Stock Movement Alerts - Newser
How to forecast Dianthus Therapeutics Inc. trends using time seriesWeekly Trend Recap & AI Powered Trade Plan Recommendations - Newser
Using R and stats models for Dianthus Therapeutics Inc. forecastingMarket Growth Summary & Long-Term Safe Investment Ideas - Newser
Analyzing Dianthus Therapeutics Inc. with multi timeframe charts2025 Performance Recap & Reliable Volume Spike Trade Alerts - Newser
Dianthus Therapeutics, Inc. $DNTH Shares Purchased by Charles Schwab Investment Management Inc. - Defense World
Dianthus Therapeutics, Inc. $DNTH Shares Sold by Vanguard Group Inc. - Defense World
Dianthus Therapeutics Inc. Stock Flags Risk Zone in Volatility IndexWeekly Trade Summary & Safe Investment Capital Preservation Plans - beatles.ru
Using fundamentals and technicals on Dianthus Therapeutics Inc.Weekly Trend Report & Entry and Exit Point Strategies - Newser
How institutional ownership impacts Dianthus Therapeutics Inc. stockGap Up & High Yield Stock Recommendations - Newser
Q3 EPS Estimate for Dianthus Therapeutics Reduced by Analyst - MarketBeat
Can a trend reversal in Dianthus Therapeutics Inc. lead to recoveryJuly 2025 Momentum & Risk Adjusted Swing Trade Ideas - Newser
Is Dianthus Therapeutics Inc. part of any ETFJuly 2025 Pullbacks & Comprehensive Market Scan Insights - sundaytimes.kr
Candriam S.C.A. Makes New Investment in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Finanzdaten der Dianthus Therapeutics Inc-Aktie (DNTH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.96%
1.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):